An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
This study is testing a new treatment called AZD0120 for adults with Multiple Sclerosis (MS). AZD0120 is a type of CAR+ T-cell therapy, which uses your own immune cells to target specific cells in your body. The main goal is to see how safe AZD0120 is and how well people tolerate it. Researchers will be looking at this over 104 weeks. You may be able to join if you are between 18 and 60 years old and have MS. The study is currently unclear about its recruitment status.
- Study design
- This is an open-label, multi-center study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 24 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and tolerability will be evaluated from Day 1 to Day 29, and then over 104 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
At a glance
Conditions
Where it's being run
19 sites across 12 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Day 1 to day 29, and over 104 weeks
Incidence and severity of Dose Limiting Toxicity (DLT) over 104 weeks following AZD0120 administration.
- Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Day 1 to day 29, and over 104 weeks
Incidence and severity of Adverse Events (AE) over 104 weeks following AZD0120 administration.
- Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Day 1 to day 29, and over 104 weeks
Incidence and severity of Serious Adverse Events (SAE) over 104 weeks following AZD0120 administration.
- Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Day 1 to day 29, and over 104 weeks
Incidence and severity of Treatment Emergent Adverse Events (TEAE) over 104 weeks following AZD0120 administration.